Prostate cancer is a common disease and, while detection and treatment have advanced, it remains a significant cause of morbidity and mortality in men. Research suggests significant involvement of the immune system in the pathogenesis and progression of prostate cancer, indicating that immunologic therapies may benefit patients. Two immunologic factors, interleukin-2 and transforming growth factor-β, may be especially attractive therapeutic targets for prostate cancer. Specifically, an increase in interleukin-2 signaling and a decrease in transforming growth factor-β signaling might help improve immunologic recognition and targeting of tumor cells. The purpose of this review is to highlight the evidence that interleukin-2 and blockade of transforming growth factor-β could be used to target prostate cancer based on current understanding of immune function in the context of prostate cancer. Additionally, current treatments related to these two factors for prostate and other cancers will be used to strengthen the argument for this strategy.
SiegelRLMillerKDJemalA. Cancer statistics, 2016. CA Cancer J Clin2016; 66: 7–30.
2.
Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM. Guideline for the management of clinically localized prostate cancer: 2007 update. Linthicum, MD: American Urological Association, 2007.
3.
DrakeCG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol2010; 10: 580–93.
4.
StarkTLivasLKyprianouN. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol2015; 4: 455–63.
5.
SokiFNKohAJJonesJDKimYWDaiJKellerETPientaKJAtabaiKRocaHMcCauleyLK. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem2014; 289: 24560–72.
6.
LanciottiMMasieriLRaspolliniMRMinerviniAMariAComitoGGiannoniECariniMChiarugiPSerniS. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int2014; 2014: 486798–486798.
7.
ComitoGGiannoniESeguraCPBarcellos-de-SouzaPRaspolliniMRBaroniGLanciottiMSerniSChiarugiP. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene2014; 33: 2423–31.
8.
SrokaICSandovalCPChopraHGardJMPawarSCCressAE. Macrophage-dependent cleavage of the laminin receptor alpha6beta1 in prostate cancer. Mol Cancer Res2011; 9: 1319–28.
9.
YuriPHendriAZDanartoR. Association between tumor-associated macrophages and microvessel density on prostate cancer progression. Prostate Int2015; 3: 93–8.
10.
GongDShiWYiSChenHGroffenJHeisterkampN. TGFβ signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol2012; 13: 1–10.
11.
SfanosKSBrunoTCMarisCHXuLThoburnCJDeMarzoAMMeekerAKIsaacsWBDrakeCG. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and T-reg skewing. Clin Cancer Res2008; 14: 3254–61.
12.
LahatNAlexanderBLevinDRMoskovitzB. The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer Immunol Immunother1989; 28: 208–12.
13.
BhavsarNABreamJHMeekerAKDrakeCGPeskoeSBDabitaoDDe MarzoAMIsaacsWBPlatzEA. A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. Cancer Epidemiol Biomarkers Prev2014; 23: 2561–7.
14.
TischnerDWiegersGJFieglHDrachMVillungerA. Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. Cell Death Differ2012; 19: 1277–87.
15.
MercaderMBodnerBKMoserMTKwonPSParkESManeckeRGEllisTMWojcicEMYangDFlaniganRCWatersWBKastWMKwonED. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA2001; 98: 14565–70.
16.
GameiroSRMalamasASTsangKYFerroneSHodgeJW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget2016; 7: 7390–402.
17.
GrossoJFKelleherCCHarrisTJMarisCHHipkissELDe MarzoAAndersRNettoGGetnetDBrunoTCGoldbergMVPardollDMDrakeCG. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest2007; 117: 3383–92.
18.
MillerAMLundbergKOzenciVBanhamAHHellstromMEgevadLPisaP. CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients. J Immunol2006; 177: 7398–405.
19.
PandiyanPZhengLIshiharaSReedJLenardoMJ. CD4+CD25+FoxP3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol2007; 8: 1353–62.
20.
MercalliACalavitaIDugnaniECitroACantarelliENanoRMelziRMaffiPSecchiASordiVPiemontiL. Rapamycin unbalances the polarization of human macrophages to M1. Immunology2013; 140: 179–90.
21.
HiganoCSSchellhammerPFSmallEJBurchPANemunaitisJYuhLProvostNFrohlichMW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer2009; 115: 3670–9.
22.
SmallEJSchellhammerPFHiganoCSRedfernCHNemunaitisJJValoneFHVerjeeSSJonesLAHershbergRM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol2006; 24: 3089–94.
23.
Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014;106:1–9.
24.
ParkBParkJByunDParkJChiS. Mitogenic conversion of transforming growth factor-b1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res2000; 60: 3031–8.
25.
Muthusamy BP, Budi EH, Katsuno Y, Lee MK, Smith SM, Mirza AM, Akhurst RJ, Derynck R. ShcA protects against epithelial-mesenchymal transition through compartmentalized inhibition of TGF-β-induced Smad activation. PLoS Biol 2015;13:1–32.
26.
KehrlJHWakefieldLMRobertsABJakowlewSAlvarez-MonMDerynckRSpornMBFauciAS. Production of transforming growth factor b by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med1986; 163: 1037–50.
27.
BuczekMEMilesAKGreenWJohnsonCBoocockDJPockleyAGReesRCHulmanGvan SchalwykGParkinsonRHulmanJPoweDGRegadT. Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer. Oncotarget2015; 35: 1–11.
28.
ChoKHJeongKJShinSCKangJParkCGLeeHY. STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett2013; 336: 167–73.
29.
WuCChangYLinWChenWChenM. TGF beta1 expression correlates with survival and tumor aggressiveness of prostate cancer. Ann Surg Oncol2015; 22: S1587–S93.
30.
ManelNUnutmazDLittmanDR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol2008; 9: 641–9.
31.
FakhraiHDorigoOShawlerDLLinHMercolaDBlackKLRoystonISobolRE. Eradication of established intracranial rat gliomas by transforming growth factor b antisence gene therapy. Proc Natl Acad Sci1996; 93: 2909–14.
32.
BoymanOSprentJ. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol2012; 12: 180–90.
33.
McHughMDParkJUhrichRGaoWHorwitzDAFahmyTM. Paracrin co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells. Biomaterials2015; 59: 172–81.
34.
HussDJWingerRCPengHYangYRackeMKLovett-RackeAE. TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol2010; 184: 5628–36.
35.
RamalingamRLarmonierCBThurstonRDMidura-KielaMTZhengSGGhishanFKKielaPR. Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J Immunol2012; 189: 3878–93.
36.
SeoNTokuraYTakigawaMEgawaK. Depletion of IL-10- and TGF-β-producing regulatory gd T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol1999; 163: 242–9.
37.
AdlerHLMcCurdyMAKattanMWTimmeTLScardinoPTThompsonTC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol1999; 161: 182–7.
38.
SongJMuYLiCBerghAMiaczynskaMHeldinCLandstromM. APPL proteins promote TGFβ-induced nuclear transport of the TGFβ type I receptor intracellular domain. Oncotarget2016; 7: 279–92.
39.
YakymovychIYakymovychMZangGMuYBerghALandstromMHeldinC. CIN85 modulates TGFβ signaling by promoting the presentation of TGFb receptors on the cell surface. J Cell Biol2015; 210: 319–32.
40.
YuNKozlowskiJMParkIIChenLZhangQXuDDollJACrawfordSEBrendlerCBLeeC. Overexpression of transforming growth factor b1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. Urology2010; 76: 1519.e8–.e13.
41.
MishraSDengJJGowdaPSRaoMKLinCHuangTSunL. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene2014; 33: 4097–106.
42.
LiTLiRLiYZhongSChenYZhangCHuMShenZ. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol2012; 187: 1466–72.
43.
GocAAl-AzayzihAAbdallaMAl-HuseinBKavuriSLeeJMosesKSomanathPR. P21 activated kinase-1 (Pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor β expression and enhanced matrix metalloproteinase 9 secretion. J Biol Chem2013; 288: 3025–35.
LamouilleSConnollyESmythJWAkhurstRJDerynckR. TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci2012; 125: 1259–73.
46.
LiuXChenZOuyangGSongTLiangHLiuWXiaoW. ELL Associated Factor 2 (EAF2) inhibits transforming growth factor β signaling through a direct interaction with Smad3. J Biol Chem2015; 290: 25933–45.
47.
CollazoJZhuBLarkinSMartinSKPuHHorbinskiCKoochekpourSKyprianouN. Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer. Cancer Res2014; 74: 2362–76.
48.
MilesFKurtogluSAhmerCSooriMFavateJSSikesRA. Transforming growth factor-β signaling induced during prostate cancer cell death and neuroendocrine differentiation is mediated by bone marrow stromal cells. Prostate2015; 75: 1802–13.
49.
GranucciFFeauSAngeliVTrotteinFRicciardi-CastagnoliP. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol2003; 170: 5075–81.
50.
LiaoWLinJXWangLLiPLeonardWJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol2011; 12: 551–9.
51.
WuHChangCWanLWuCTsaiFChenW. IL-2 gene C/T polymorphism is associated with prostate cancer. J Clin Lab Anal2006; 20: 245–9.
52.
DreicerRStadlerWMAhmannFRWhitesideTBizouarneNAcresBLimacherJMSquibanPPantuckA. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs2008; 27: 379–86.
53.
QuioxELenaHLosonczyGForgetFChouaidCPapaiZGervaisROttensmeierCSzczsnaAKazarnowiczABeckJTWesteelVFelipEDebieuvreDMadroszykAAdamJLacosteGTavernaroABastienBHallvardCPalancheTLimacherJM. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol2016; 17: 212–23.
54.
DieliFVermijlenDFulfaroFCaccamoNMeravigliaSCiceroGRobertsABuccheriSD'AsaroMGebbiaNSalernoAEberlMHaydayAC. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res2007; 67: 7450–7.
55.
BrillTHKublerHRVan RandenborghHFendFPohlaHBreulJHartungRPaulRSchendelDJGansbacherB. Allogenic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer – a phase I clinical trial. J Gene Med2007; 9: 547–60.
56.
BrillTHKublerHRPohlaHBuchnerAFendFSchusterTvan RandenbourghHPaulRKummerTPlankCEiseleBBreulJHartungRSchendelDJGansbacherB. Therapeutic vaccination with an interleukin-2-interferon-γ-secreting allogenic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther2009; 20: 1641–51.
57.
BelldegrunATsoCZismanANaitohJSaidJPantuckAHinkelAdeKernionJFiglinR. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther2001; 12: 883–92.
58.
SugimotoYHirotaMYoshikawaKSumitomoMNakamuraKUedaRNiwaRSuzawaTYamasakiMShitaraKKatoTNakamuraK. The therapeutic potential of a novel PMSA antibody and its IL-2 conjugate in prostate cancer. Anticancer Res2014; 34: 89–98.
59.
WuZXuY. IL-15Ra-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+T cells proliferation and activation. J Mol Cell Biol2010; 2: 217–22.
NanusDMMilowskyMIKostakogluLSmith-JonesPMVallabahajosulaSGoldsmithSJBanderNH. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol2003; 170(6 Pt 2): S84–8. discussion S8–9.
62.
MadanRAGulleyJLSchlomJSteinbergSMLiewehrDJDahutWLArlenPM. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res2008; 14: 4526–31.
63.
ArlenPMGulleyJLToddNLiebermanRSteinbergSMMorinSBastianAMarteJTsangKYBeethamPGrosenbachDWSchlomJDahutW. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol2005; 174: 539–46.
64.
AgahRMalloyBKernerMMazumderA. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J Immunol1989; 143: 3093–9.
65.
ThompsonJALeeDJCoxWWLindgrenCGCollinsCNeraasKADenninRAFeferA. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res1987; 47: 4202–7.
66.
RedmondWLGoughMJCharbonneauBRatliffTLWeinbergAD. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol2007; 179: 7244–53.
67.
LinchSNKasiewiczMJMcNamaraMJHilgart-MartiszusIFFarhadMRedmondWL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci USA2016; 113: E319–27.
EdwardsMJHenifordBTKlarEADoakKWMillerFN. Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest1992; 90: 637–41.
70.
GilliesSDLanYHettmannTBrunkhorstBSunYMuellerSOLoK. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res2011; 17: 3674–85.
71.
AbdulMHooseinN. Differences in the expression and effects of interleukin-1 and -2 on androgen-sensitive and -insensitive human prostate cancer cell lines. Cancer Lett2000; 149: 37–42.
72.
EspevikTWaageAFaxvaagAShalabyMR. Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of Interleukin-1b and transforming growth factor-β. Cell Immunol1990; 126: 47–56.
73.
BoscoMCEspinoza-DelgadoISchwabeMRussellSMLeonardWJLongoDLVaresioL. The γ subunit of the interleukin-2 receptor is expressed in human monocytes and modulated by interleukin-2, interferon γ and transforming growth factor β1. Blood1994; 83(12): 3462–7.
74.
SaitoSMoriiTEnomotoMSakakuraSNishikawaKNaritaNIchijoM. The effect of interleukin 2 and transforming growth factor-β2 (TGF-β2) on the proliferation and natural killer activity of decidual CD16− CD56bright natural killer cells. Cell Immunol1993; 152: 605–13.
75.
RookAHKehrlJHWakefieldLMRobertsABSpornMBBurlingtonDBLaneHCFauciAS. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol1986; 136: 3916–20.
ZhangQYangXJKunduSDPinsMJavonovicBMeyerRKimSGreenbergNMKuzelTMeagherRGuoYLeeC. Blockade of transforming growth factor-β signaling in tumor-reactive CD8+T cells activates the antitumor immune cell response. Mol Cancer Ther2006; 5: 1733–43.
78.
AlvarezMBouchlakaMNSckiselGDSungurCMChenMMurphyWJ. Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells. J Immunol2014; 193: 1709–1716.
79.
Wojtowicz-PragaSVermaUMWakefieldLEstebanJMHartmannDMazumderA. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor b antibody. J Immunother1996; 19: 169–75.
80.
ClaytonAMitchellJPCourtJMasonMDTabiZ. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res2007; 67: 7458–66.
81.
GridleyDSSuraSSUhmJLinCKetteringJD. Effects of anti-transforming growth factor-β antibody and interleukin-2 in tumor-bearing mice. Cancer Biother1993; 8: 159–70.
82.
KangRTangDLotzeMTZehHJ. Autophagy is required for IL-2-mediated fibroblast growth. Exp Cell Res2013; 319: 556–65.
83.
MaoXWKetteringJDGridleyDS. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-β in a murine tumor model. Cancer Biother1994; 9: 317–27.
TatanoYShimizuTTomiokaH. Unique macrophages different from M1/M2 macrophages inhibit T cell mitogenesis while upregulating Th17 polarization. Sci Rep2014; 4: 4146–4146.
86.
BrabletzTPfeufferISchorrESiebeltFWirthTSerflingE. Transforming growth factor-β and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol1993; 13: 1155–62.
87.
LiBSehajpalPKKhannaAVlassaraHCeramiAStenzelKHSuthanthiranM. Differential regulation of transforming growth factor-β and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med1991; 174: 1259–62.
88.
ZhengSGWangJHGrayJDSoucierHHorwitzDA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-, and IL-10. J Immunol2004; 172: 5213–21.
